AtlasVector
Launch AtlasVector →
URGN27.00+0.90 (+3.45%) session● PRIOR SESSION CLOSE
AtlasVector › Decision Feed › URGN

URGNcited research thesis

URGN — what changed and why it matters

House verdict · URGN · multi-desk debate + self-falsification

No sealed verdict on URGN yet

No debate has been run on URGN; debates rotate through a watchlist. The conviction call below is the signal engine’s output — one input to a debate, not a multi-desk verdict. Sealed debates on other names, each with its falsification check, are available.
Open the Glass Box →
Individual · $49 a monthThe conviction call on URGN — outside the public coverage list

Covered names include the conviction call in the sealed record at no charge. URGN is outside public coverage; running the signal engine on it requires a seat. The panels above do not depend on it.

Start checkout →

PRE-EARNINGS THESIS — written 2026-08-15, before the 2026-11-04 earnings report; nothing below reflects that report. A refresh is queued for the session a covered name reports or moves sharply. A same-session re-derive is queued when a covered name prints or moves sharply; until the refreshed read lands, nothing below reflects that report.

0 of 11 figures below re-derived from a sourcewritten 2026-08-15

This thesis is 89 days old. Statements below are as of 2026-08-15.

URGN — what moved and why today

Context (knowledge graph)

AtlasVector tracks 10 related entities for URGN in its knowledge graph. [c1]

What changed

  • sell-side note Maintains Buy on UroGen Pharma, Raises Price Target to $58
  • HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75
  • sell-side note Maintains Buy on UroGen Pharma, Raises Price Target to $60

Valuation spine (rich/cheap)

[c5]

Key takeaways
  • sell-side note Maintains Buy on UroGen Pharma, Raises Price Target to $58
  • HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75
  • sell-side note Maintains Buy on UroGen Pharma, Raises Price Target to $60
Headlines · URGN AS OF 2026-11-13 00:56Z
  1. 11-04 14:05ZUrogen Pharma (URGN) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research
  2. 11-02 13:00ZUroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerGlobeNewswire Inc.

Provenance

verdicts, debates and hash-chained audit seals recorded against URGN
Instruments 1
  • URGN2026-10-29
Session bars 5
  • URGN · Thu Oct 29 session barURGN2026-10-29
  • URGN · Wed Oct 28 session barURGN2026-10-28
  • URGN · Tue Oct 27 session barURGN2026-10-27
  • URGN · Mon Oct 26 session barURGN2026-10-26
  • URGN · Fri Oct 23 session barURGN2026-10-23
Screen metrics 1
  • URGN · screen metrics · Thu Oct 29URGN2026-10-29

7 recorded entities · 6 links. synthetic = the row is flagged as built on synthetic inputs; no provenance = the store holds no synthetic flag for the row. Unmarked rows are flagged non-synthetic. Chain seals list sequence number, event key and SHA-256 chain hash. Verify seal opens the verdict's proof panel, where the sealed record is re-hashed in the browser and compared against the seal.

Cited sources · 5

[c1]AtlasVector knowledge graphgraph context for URGN
[c2]Newswiresell-side note Maintains Buy on UroGen Pharma, Raises Price Target to $58
[c3]NewswireHC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75
[c4]Newswiresell-side note Maintains Buy on UroGen Pharma, Raises Price Target to $60
[c5]AtlasVector valuation spineconsensus valuation

The full record is in AtlasVector.

Standing monitors, multi-desk debate, audited paper trading and a persistent research record.

Open AtlasVector →